SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,778,802 | -12.7% | 286,829 | -2.8% | 0.18% | -2.2% |
| Q2 2023 | $8,910,820 | -19.1% | 295,158 | -2.9% | 0.18% | -18.8% |
| Q1 2023 | $11,011,890 | +0.4% | 303,944 | -1.2% | 0.22% | 0.0% |
| Q4 2022 | $10,968,596 | +3.7% | 307,502 | -1.6% | 0.22% | +2.3% |
| Q3 2022 | $10,582,000 | +13.8% | 312,617 | -2.7% | 0.22% | +19.0% |
| Q2 2022 | $9,296,000 | -17.5% | 321,433 | -7.8% | 0.18% | +2.2% |
| Q1 2022 | $11,272,000 | +7.8% | 348,764 | -2.8% | 0.18% | +18.4% |
| Q4 2021 | $10,460,000 | +6.9% | 358,717 | -2.2% | 0.15% | +4.1% |
| Q3 2021 | $9,783,000 | -16.3% | 366,823 | -3.3% | 0.15% | -16.1% |
| Q2 2021 | $11,683,000 | +17.4% | 379,436 | -0.1% | 0.17% | +16.8% |
| Q1 2021 | $9,948,000 | +36.8% | 379,968 | +31.5% | 0.15% | +11.2% |
| Q4 2020 | $7,272,000 | +30.9% | 289,028 | +8.4% | 0.13% | +8.9% |
| Q3 2020 | $5,555,000 | +2.1% | 266,540 | +16.3% | 0.12% | -5.4% |
| Q2 2020 | $5,442,000 | +31.1% | 229,116 | -0.7% | 0.13% | +5.7% |
| Q1 2020 | $4,151,000 | -28.1% | 230,765 | -5.2% | 0.12% | +9.8% |
| Q4 2019 | $5,775,000 | -59.0% | 243,455 | -52.5% | 0.11% | -60.0% |
| Q3 2019 | $14,090,000 | -35.4% | 512,735 | -22.2% | 0.28% | -33.5% |
| Q2 2019 | $21,816,000 | -18.9% | 659,281 | -14.1% | 0.42% | -23.6% |
| Q1 2019 | $26,893,000 | -3.6% | 767,504 | -8.6% | 0.55% | -21.4% |
| Q4 2018 | $27,905,000 | +8.2% | 840,017 | +64.0% | 0.70% | +31.5% |
| Q3 2018 | $25,787,000 | -27.6% | 512,147 | -13.9% | 0.53% | -34.2% |
| Q2 2018 | $35,617,000 | +335.9% | 595,096 | +233.6% | 0.81% | +313.3% |
| Q1 2018 | $8,171,000 | -65.5% | 178,400 | -70.0% | 0.20% | -66.6% |
| Q4 2017 | $23,705,000 | +4.7% | 594,862 | +5.1% | 0.59% | -5.6% |
| Q3 2017 | $22,636,000 | +215.1% | 565,900 | +239.5% | 0.62% | +198.6% |
| Q2 2017 | $7,184,000 | +41.3% | 166,675 | +2.6% | 0.21% | +49.6% |
| Q1 2017 | $5,085,000 | +16.5% | 162,450 | -6.0% | 0.14% | +13.9% |
| Q4 2016 | $4,366,000 | +2.2% | 172,900 | +0.1% | 0.12% | +1.7% |
| Q3 2016 | $4,270,000 | +21.7% | 172,650 | +0.2% | 0.12% | +22.4% |
| Q2 2016 | $3,510,000 | +40.0% | 172,300 | +4.8% | 0.10% | +44.1% |
| Q1 2016 | $2,508,000 | +49.7% | 164,450 | +31.9% | 0.07% | +61.9% |
| Q4 2015 | $1,675,000 | +105.8% | 124,650 | +114.8% | 0.04% | +121.1% |
| Q3 2015 | $814,000 | – | 58,025 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthInvest Partners AB | 335,000 | $8,934,000 | 13.38% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,016,665 | $27,114,000 | 2.46% |
| Bruce & Co., Inc. | 402,105 | $10,724,000 | 2.28% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $7,934,000 | 1.91% |
| ARMISTICE CAPITAL, LLC | 3,900,000 | $104,013,000 | 1.76% |
| Bridge City Capital, LLC | 108,884 | $2,904,000 | 1.32% |
| S&T BANK/PA | 316,098 | $8,430,000 | 1.31% |
| Kent Lake Capital LLC | 100,000 | $2,667,000 | 1.15% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 331,140 | $8,832,000 | 1.02% |
| Prairiewood Capital, LLC | 45,297 | $1,208,000 | 0.99% |